All News
RheumNow Podcast – COVID-19 Responds to Steroids (7.24.20)
Dr. Jack Cush reviews the News and Journal Reports from the past week on RheumNow.com.
Read Article
Low Risk of COVID in Biologic Treated Rheum Patients
In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population.
Read Article
For TNF Response in RA, Weight Matters
Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.
Compared with patients with normal weight, patients in obesity class II, whose body mass index (BMI) was 35 to 39.9, had a hazard ratio for shorter drug survival (i.e., the drug's effectiveness, safety, and tolerability) of 1.28 (95% CI 1.06-1.54), while those in obesity class III, whose BMI exceeded 40, had a hazard ratio of 1.67 (95% CI 1.29-2.18), according to Sytske Anne Bergstra, PhD, of Leiden University Medical Center in the Netherlands, and colleagues.
Risankizumab Outduels Secukinumab in Psoriasis
The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.
Read Article
RECOVERY Trial: Dexamethasone in COVID-19
Inflammatory events following infection with SARS-CoV-2 can often worsen the morbid or mortal outcomes with COVID, yet it has been unclear if glucocorticoids may modulate inflammation-mediated damage and lung injury. The RECOVERY trial reports that dexamethasone (DEX) use lowered 28-day mortality among COVID-19 patients requiring respiratory support.
The RECOVERY trial was performed in the UK and enrolled hospitalized COVID-19 patients who were randomly assigned patients to usual care alone or the addition of oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days. The primary outcome was 28-day mortality.
Meloxicam Superior to Placebo and Cognitive Behavioral Therapy in Knee OA
Pain management in knee osteoarthritis (OA) is confounded by studies showing less is equal to usual standards of care. A recent trial showed that meloxicam was superior to placebo or cognitive behavioral therap (CBT); although the differences were small.
Read Article
HCQ May Help Prevent Fetal Heart Block
Hydroxychloroquine (HCQ) helped reduce recurrent maternal autoantibody-mediated congenital heart block (CHB) in fetuses, an open-label study suggested.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM NEJM ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Victoria Shanmugam VickiShanmugam ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
